Inhibikase Therapeutics Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease (PD), Parkinson’s-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson’s disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
/ 
Frequently asked questions
To buy Inhibikase Therapeutics Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Inhibikase Therapeutics Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Inhibikase Therapeutics Inc. is IKT:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Inhibikase Therapeutics Inc. has its primary listing on NASDAQ. You can trade Inhibikase Therapeutics Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Inhibikase Therapeutics Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Inhibikase Therapeutics Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Inhibikase Therapeutics Inc..